IPIERIAN
We are using induced pluripotent stem cells for drug discovery and development. Focused on neurodegenerative diseases such as SMA, ALS and Parkinson's, and other major unmet medical needs.
IPIERIAN
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
2007-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.ipierian.com
Total Employee:
11+
Status:
Closed
Contact:
650-872-4700
Email Addresses:
[email protected]
Total Funding:
80.67 M USD
Technology used in webpage:
IPv6 Cloudflare Cloudflare Hosting Cloudflare Network Error Logging Cloudflare DNS Cloudflare SSL LiteSpeed Drupal
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-07-08 | iZumi Bio | iZumi Bio acquired by iPierian | N/A |
Investors List
Mission BioCapital
Mission BioCapital investment in Venture Round - iPierian
Kleiner Perkins
Kleiner Perkins investment in Venture Round - iPierian
MPM Capital
MPM Capital investment in Venture Round - iPierian
SR One
SR One investment in Venture Round - iPierian
SR One
SR One investment in Series B - iPierian
Biogen Idec
Biogen Idec investment in Series B - iPierian
Highland Capital Partners
Highland Capital Partners investment in Series B - iPierian
ATEL Ventures
ATEL Ventures investment in Series B - iPierian
MPM Capital
MPM Capital investment in Series B - iPierian
GV
GV investment in Series B - iPierian
Official Site Inspections
http://www.ipierian.com
- Host name: 172.67.155.112
- IP address: 172.67.155.112
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "iPierian"
iPierian - Crunchbase Company Profile & Funding
IPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s. ... Products. Resources. Pricing. Resources. Log In. …See details»
About Us | iPierian
The monoclonal antibody development programs evolve from iPierian’s proprietary iPSC technology for disease modeling – utilizing patient-derived cortical neurons, motor neurons, …See details»
iPierian Company Profile 2024: Valuation, Investors, Acquisition ...
IPierian General Information Description. Developer of therapies designed to treat neurodegenerative disease. The company engages in the research and development of …See details»
Investors | iPierian
IPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital, Google Ventures, SR One, FinTech Global Capital, Mitsubishi UFJ Capital, Biogen Idec New …See details»
Leadership Team | iPierian
Adam Rosenthal, Ph.D., has served as iPierian’s Senior Director of Strategic and Corporate Development since August 2010, working across Finance, Business Development, R&D, and …See details»
iPierian - Funding, Financials, Valuation & Investors - Crunchbase
IPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s. Search Crunchbase. ... How much funding has this …See details»
iPierian - Crunchbase
IPierian is a drug discovery platform that develops therapies for neurodegenerative diseases such as SMA, ALS, and Parkinson’s. Search Crunchbase Start Free TrialSee details»
iPierian - VentureRadar
IPierian, Inc. is a biotechnology company developing novel therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau …See details»
KYOTO UNIVERSITY, iPS ACADEMIA JAPAN, AND iPIERIAN …
IPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and the discovery and development of innovative …See details»
Bristol-Myers Squibb Acquires iPierian, Inc.
Apr 29, 2014 Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company …See details»
Home | iPierian
IPierian is a biopharmaceutical company creating a revolutionary new paradigm for drug discovery in neurodegenerative diseases Latest News. Congratulations to our SAB member Dr. Shinya …See details»
iPierian | Stanford Graduate School of Business
The company must decide between three major directions—tools, drug development of therapeutics—in which it can steer the business and continue to develop its technology. …See details»
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular ...
Jul 8, 2009 iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating …See details»
iPierian - Contacts, Employees, Board Members, Advisors & Alumni
Organization. iPierian . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
Promising stem cell start-ups merge, add $11.5M - Fierce Biotech
Jul 8, 2009 Pierian and iZumi Bio will create iPierian, which will be helmed Two stem cell technology start-ups have agreed to merge, snagging an additional $11.5 million in fresh …See details»
BMS buys Alzheimer’s player iPierian in $725m deal
Apr 30, 2014 Takes control of several promising candidates for neurodegenerative diseasesSee details»
People | iPierian
To find out more about our team, please visit these pages: Leadership Team; Board of Directors; Scientific AdvisorsSee details»
Technology Overview | iPierian
IPierian’s approach to developing novel therapeutics is enabled by the company’s proprietary capabilities in induced pluripotent stem cell (iPSC) technology. Skin biopsy-derived fibroblasts …See details»
iPierian - Tech Stack, Apps, Patents & Trademarks - Crunchbase
IPierian uses 11 technology products and services including HTML5, Google Fonts, and Cloudflare CDN, according to G2 Stack. iPierian is actively using 7 technologies for its …See details»
Product Development Overview | iPierian
The monoclonal antibody development programs evolve from iPierian’s proprietary iPSC technology for disease modeling – utilizing patient-derived cortical neurons, motor neurons, …See details»